Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk
Report provides guidance on reducing CV risk in patients with T2DM and atherosclerotic CV disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.